As previously reported, H.C. Wainwright analyst Joseph Pantginis downgraded Mateon Therapeutics to Neutral from Buy after the FDA placed OXi4503 on partial clinical hold based on two potential dose-limiting toxicities seen in the ongoing OX1222 study in relapsed/refractory AML patients. He had been optimistic on the company's prospects based on the "compelling" OXi4503 data delivered to date, but now believes investors need to be provided increased comfort that the company can fund operations and whether dosing at 9.76 mg/m2 can be a viable dose for a path forward for OXi4503. Mateon is up 6% to 15c per share in early trading.